New indication for J&J's Remicade approved by FDA

05/19/2005 | Bloomberg Businessweek

The FDA approved Johnson & Johnson's Remicade for reduction of psoriatic arthritis, putting the product in competition with Amgen's blockbuster arthritis drug Enbrel. Both drugs already are approved for treatment of other inflammatory diseases such as rheumatoid arthritis and ankylosing spondylitis.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA